Patents Examined by Emily Bernhardt
  • Patent number: 11179391
    Abstract: The present invention provides a compound as shown in general formulas (I) or (II) and a pharmaceutically acceptable salt, an isomer or a mixture form thereof, a solvate, a polymorph, a stable isotope derivative, or a prodrug of the same. The compound of the present invention has CDK kinase inhibitory activity and can be used in treating a disease related to CDK kinase, such as a cancer.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: November 23, 2021
    Inventor: Fuyao Zhang
  • Patent number: 11180484
    Abstract: The present invention provides a selection of compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: November 23, 2021
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: Rebecca Louise Davie, Hanna Joy Edwards, David Michael Evans, Simon Teanby Hodgson, Stephen John Pethen, David Philip Rooker
  • Patent number: 11180490
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: November 23, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joanne M. Smallheer, Nicholas R. Wurtz, Meriah Neissel Valente, Karen A. Rossi, Ellen K. Kick
  • Patent number: 11168094
    Abstract: The present invention relates to a novel quinolinone derivative compound that regulates intracellular signal transduction mediated by TSLP and IL-33 to exhibit efficacy in preventing or treating allergic diseases such as asthma or atopic dermatitis. The quinolinone derivative compound of the present invention can effectively suppress inflammatory responses of allergic diseases such as asthma or atopic dermatitis. The present invention also relates to a pharmaceutical composition including the quinolinone derivative compound. The pharmaceutical composition of the present invention can be used to fundamentally prevent or treat various allergic and asthmatic diseases.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: November 9, 2021
    Assignee: Azcuris Co., Ltd.
    Inventors: Youngjoo Byun, Young Ho Jeon, Kiho Lee, Ki Yong Lee, Yong Woo Jung, Sang-Hyun Son
  • Patent number: 11168102
    Abstract: The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same. Modulators of SOS1 have the following general structure of the Formula (II), or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein the variables are as defined herein.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: November 9, 2021
    Assignee: Revolution Medicines, Inc.
    Inventors: Adrian L. Gill, Andreas Buckl, Elena S. Koltun, Naing Aay, Arlyn A. Tambo-ong, Severin Thompson, Micah James Gliedt, John E. Knox, James Cregg, Anne V. Edwards, Yang Liu, G. Leslie Burnett
  • Patent number: 11166958
    Abstract: Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: November 9, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • Patent number: 11155542
    Abstract: The present invention relates to the general field of treatment of infectious diseases of mammals (humans and animals) caused by bacteria, in particular to the treatment of diseases like tuberculosis (TB), Buruli ulcer and leprosy caused by mycobacteria. The invention aims at the generation of a new series of benzothiazinone compounds having the potential to overcome the above mentioned problems. In a preferred embodiment the invention is concerned with compounds of the general formula (I) wherein R1 represents NO2, R2 represents CF3, at least one of the substituents R3 and R4 is OH, SR14, NHR15, CN, N3, a saturated or unsaturated, optionally halogenated, linear or branched aliphatic radical having 1-4 carbon atoms, linear or branched C1-C4 alkoxy, C1-C4 acyl, and the other of R3 and R4 may in addition be hydrogen, R6 represents a 2-methyl-1,4-dioxa-8-azaspiro[4.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: October 26, 2021
    Assignees: University of Notre Dame Du Lac
    Inventors: Florian Kloss, Sebastian Schieferdecker, Axel Brakhage, Julia Dreisbach, Marvin J. Miller, Ute Mollmann, Kamil Philip Wojtas
  • Patent number: 11155534
    Abstract: Disclosed are an EGFR inhibitor free base or acid salt polycrystalline form, a preparation method therefor, and an application thereof. The present invention specifically relates to an N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide free base or acid salt polycrystalline form, a preparation method therefor, and an application of the polycrystalline form in preparing a drug for treating an EGFR mutant activity-mediated disease. The present invention is used for inhibiting the activity of an L858R EGFR mutant, a T790M EGFR mutant and an exon 19 deletion activating mutant etc., may be widely applied in preventing and treating cancer, especially non-small cell lung cancer and other related diseases, and is expected to develop into a new generation of EGFR inhibitors.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: October 26, 2021
    Assignees: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanghai Hansoh Biomedical Co., Ltd.
    Inventors: Zhongke Chen, Fuping Liu, Lei Liu, Rudi Bao
  • Patent number: 11154519
    Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: October 26, 2021
    Assignee: United Kingdom Research and Innovation
    Inventors: Anne Bertolotti, Indrajit Das, Agnieszka Krzyzosiak, Adrien Rousseau, Kim Schneider, Anna Gudny Sigurdardottir
  • Patent number: 11123337
    Abstract: The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: September 21, 2021
    Assignee: MyoKardia, Inc.
    Inventors: Johan Oslob, Danielle Aubele, Jae Kim, Robert McDowell, Yonghong Song, Arvinder Sran, Min Zhong
  • Patent number: 11124516
    Abstract: The invention provides substituted pyrrolo[1,2-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-pyrrolo[1,2-a]pyrimidine-8-carboxarnide compounds and variants thereof.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: September 21, 2021
    Assignee: BIAL-BIOTECH INVESTMENTS, INC.
    Inventors: Renato T. Skerlj, Elyse Marie Josee Bourque, Peter T. Lansbury, William J. Greenlee, Andrew C. Good
  • Patent number: 11117871
    Abstract: The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: September 14, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Minhua Chen, Yanfeng Zhang, Jinqiu Wang, Xiaoyu Zhang
  • Patent number: 11104679
    Abstract: The present disclosure relates to various solid state forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine and methods of making the same. Such forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine are useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: August 31, 2021
    Assignee: MINGSIGHT PHARMACEUTICALS, INC.
    Inventors: Kay Olmstead, Julian Northen
  • Patent number: 11104665
    Abstract: The present invention relates to novel pyridazines according to formula (I) processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of diseases and disorders mediated by Autotaxin.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: August 31, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Gerald Juergen Roth, Tom Bretschneider, Christian Andreas Kuttruff
  • Patent number: 11091461
    Abstract: The invention provides a method for producing a crystal of a uracil compound with high purity by a process which can be carried out in an industrial scale. Specifically, the invention provides a method for producing a crystal of a uracil compound, wherein the method involves dissolving a composition containing a uracil compound represented by formula (1) in organic solvents consisting of a C3-C6 alcohol solvent and an aromatic solvent to obtain a solution, and precipitating a crystal of said uracil compound from the solution.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: August 17, 2021
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Yuki Sato
  • Patent number: 11077050
    Abstract: The instant invention provides pharmaceutical formulations for a long acting injectable drug product comprising a suspension of doravirine for parenteral administration via intramuscular or subcutaneous routes. The drug product can be used for the treatment or prophylaxis of infection by HIV or for the treatment, prophylaxis, or delay in the onset of AIDS (acquired immunodeficiency syndrome) or ARC (AIDS related complex).
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: August 3, 2021
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Sachin Mittal, Irina Kazakevich, Himanshu Bhattacharjee, Peter Bakker, Luke Schenck, David J. Goldfarb, Amitava Mitra, Donna Carroll, Nazia Khawaja
  • Patent number: 11078208
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: August 3, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Elbert Chin, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, John O. Link, Nathan Shapiro, Teresa Alejandra Trejo Martin, Zheng-Yu Yang
  • Patent number: 11077108
    Abstract: In various embodiments novel allosteric antagonists of the CRFR1 receptor are provided. It discovered that allosteric CRFR1 receptor antagonists are effective to modulate p-Tau levels in Alzheimer's disease (AD) models. In one illustrative embodiment, a compound that is a CRFR1 receptor antagonist is a compound according to the formula or a pharmaceutically acceptable salt, ester, amide, solvate, or prodrug thereof.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: August 3, 2021
    Assignee: The Regents of the University of California
    Inventors: Mohammad Parvez Alam, Varghese John, Barbara Jagodzinska
  • Patent number: 11077100
    Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: August 3, 2021
    Assignees: RaQualia Pharma Inc., Asahi Kasei Pharma Corporation
    Inventors: Hirohide Noguchi, Yoshimasa Arano, Kazuo Ando, Kazuki Toyoshima, Toshihiko Sone
  • Patent number: 11072610
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: July 27, 2021
    Assignee: Novartis AG
    Inventors: Christopher Becker, Xiaolin Li, Peichao Lu, Naomi Samadara Rajapaksa, David Charles Tully, Xiaojing Michael Wang, Qian Zhao